Recently, a new study revealed that UFMylation of DDRGK1 can ameliorate obesity, hepatic lipogenesis, and insulin resistance in mice with MASLD, indicating an involvement of the UFMylation pathway in MASLD progression [27]. The gene discussed is DDRGK1; the disease is metabolic dysfunction-associated steatotic liver disease.